U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H10F3N3O4
Molecular Weight 317.2207
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NILUTAMIDE

SMILES

CC1(C)NC(=O)N(C1=O)C2=CC=C(C(=C2)C(F)(F)F)[N+]([O-])=O

InChI

InChIKey=XWXYUMMDTVBTOU-UHFFFAOYSA-N
InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)

HIDE SMILES / InChI

Molecular Formula C12H10F3N3O4
Molecular Weight 317.2207
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207631Orig1s000lbl.pdf

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. The relative binding affinity of nilutamide at the androgen receptor is less than that of bicalutamide, but similar to that of hydroxuflutamide. Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. This blockade of androgen receptors may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis. Nilutamide is used in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2). Nilutamide is sold under the brand names Nilandron (US), Anandron (CA)).

CNS Activity

Curator's Comment: Like flutamide and bicalutamide, nilutamide is able to cross the blood-brain-barrier and has central antiandrogen actions.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NILANDRON

Approved Use

Metastatic Prostate Cancer Nilutamide Tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2).

Launch Date

8.4300477E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.3 mg/L
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.3 mg/L
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
84 mg × h/L
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
49 h
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
56 h
0.3 g single, oral
dose: 0.3 g
route of administration: Oral
experiment type: SINGLE
co-administered:
NILUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
DLT: Nausea, Vomiting...
Disc. AE: Hot flashes, Interstitial lung disease...
Dose limiting toxicities:
Nausea (7.5%)
Vomiting (7.5%)
AEs leading to
discontinuation/dose reduction:
Hot flashes (5.7%)
Interstitial lung disease (3.8%)
Visual disturbance NOS (1.9%)
Pruritus (1.9%)
Dizziness (1.9%)
Headache (1.9%)
Hepatic enzyme increased (1.9%)
Sources: Page: p.1075
13 g single, oral
Overdose
unhealthy, 79
n = 1
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 79
Sex: M
Population Size: 1
Sources:
Disc. AE: Vomiting, Diarrhoea...
AEs leading to
discontinuation/dose reduction:
Vomiting (moderate)
Diarrhoea (moderate)
Sources:
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Disc. AE: Gastrointestinal disorders, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorders
Nausea
Vomiting
Malaise
Headache
Dizziness
Sources:
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Co-administed with::
leuprolide
Sources: Page: p.8
unhealthy
n = 209
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 209
Sources: Page: p.8
Disc. AE: Visual disturbances...
AEs leading to
discontinuation/dose reduction:
Visual disturbances (1 - 2)
Sources: Page: p.8
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.3
Disc. AE: Interstitial pneumonitis, Pulmonary fibrosis...
AEs leading to
discontinuation/dose reduction:
Interstitial pneumonitis (2%)
Pulmonary fibrosis (grade 5, rare)
Sources: Page: p.3
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.4
Disc. AE: Liver injury...
AEs leading to
discontinuation/dose reduction:
Liver injury (severe, rare)
Sources: Page: p.4
AEs

AEs

AESignificanceDosePopulation
Dizziness 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Headache 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Hepatic enzyme increased 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Pruritus 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Visual disturbance NOS 1.9%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Interstitial lung disease 3.8%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Hot flashes 5.7%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Nausea 7.5%
DLT
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Vomiting 7.5%
DLT
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources: Page: p.1075
unhealthy, 47-93
n = 53
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 47-93
Sex: M
Population Size: 53
Sources: Page: p.1075
Diarrhoea moderate
Disc. AE
13 g single, oral
Overdose
unhealthy, 79
n = 1
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 79
Sex: M
Population Size: 1
Sources:
Vomiting moderate
Disc. AE
13 g single, oral
Overdose
unhealthy, 79
n = 1
Health Status: unhealthy
Condition: Metastatic prostate cancer
Age Group: 79
Sex: M
Population Size: 1
Sources:
Dizziness Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Gastrointestinal disorders Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Headache Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Malaise Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Nausea Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Vomiting Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 4
Sources:
Visual disturbances 1 - 2
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Co-administed with::
leuprolide
Sources: Page: p.8
unhealthy
n = 209
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Population Size: 209
Sources: Page: p.8
Interstitial pneumonitis 2%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.3
Pulmonary fibrosis grade 5, rare
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.3
Liver injury severe, rare
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Metastatic prostate cancer
Sex: M
Sources: Page: p.4
PubMed

PubMed

TitleDatePubMed
Nilutamide: possible utility as a second-line hormonal agent.
2001 Dec
Flavonoids can block PSA production by breast and prostate cancer cell lines.
2002 Mar
Therapeutic androgen receptor ligands.
2003
[Fatal fulminating hepatitis induced by nilutamide].
2003 Dec
Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug.
2003 Dec
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.
2003 Jan
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
2003 May
Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate.
2003 Nov 20
Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
2004
Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines.
2004 Jun
Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans.
2004 May-Jun
Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.
2004 Nov 4
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
2005 Aug
[From the finger to the eye!...].
2005 Jul
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Combined androgen blockade: the case for bicalutamide.
2005 Mar
Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives.
2005 Nov 15
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
2005 Oct
Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
2005 Sep
Androgenic and antiandrogenic effects and expression of androgen receptor in mouse embryonic stem cells.
2006 Apr
Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3.
2006 Apr
Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
2006 Aug
Metabolism of nilutamide in rat lung.
2006 Jan 12
Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.
2006 Jun
Combined androgen blockade: an update.
2006 May
[Keyrole of endocrinology in the victory against prostate cancer].
2006 Sep
A bifunctional colchicinoid that binds to the androgen receptor.
2007 Aug
New therapeutic targets in the treatment of prostate cancer.
2007 Jan
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
2007 Jul
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
2007 Jun 1
Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
2007 Mar
Screening of 397 chemicals and development of a quantitative structure--activity relationship model for androgen receptor antagonism.
2008 Apr
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
2008 Jan 24
Strategies for prostate cancer prevention: Review of the literature.
2008 Jul
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
2008 Jun
Watchful waiting beats androgen deprivation therapy in early prostate cancer.
2008 Nov 5
Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
2008 Oct
FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects.
2008 Sep 24
Fasting and cancer treatment in humans: A case series report.
2009 Dec 31
Role of maximum androgen blockade in advanced prostate cancer.
2009 Jan
Genotoxic and endocrine activities of bis(hydroxyphenyl)methane (bisphenol F) and its derivatives in the HepG2 cell line.
2009 Jan 8
Integrating statistical predictions and experimental verifications for enhancing protein-chemical interaction predictions in virtual screening.
2009 Jun
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
2009 Nov 15
Hormonal therapy of prostate cancer.
2010
Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway.
2010 Apr
The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.
2010 Apr 20
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
2010 Feb 24
Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor.
2010 Jan 26
Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice.
2010 Sep
Patents

Sample Use Guides

The recommended dosage is 300 mg once a day for 30 days, followed thereafter by 150 mg once a day. Nilutamide Tablets can be taken with or without food.
Route of Administration: Oral
In Vitro Use Guide
At concentrations expected in the human liver (110 uM), nilutamide inhibited hexobarbital hydroxylase, benzphetamine N-demethylase, benzo(a)pyrene hydroxylase and 7-ethoxycoumarin O-deethylase activities by 85, 40, 35 and 25%, respectively in human liver microsomes.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:16:32 UTC 2023
Edited
by admin
on Wed Jul 05 23:16:32 UTC 2023
Record UNII
51G6I8B902
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NILUTAMIDE
EP   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
nilutamide [INN]
Common Name English
NILUTAMIDE [ORANGE BOOK]
Common Name English
5,5-DIMETHYL-3-(.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-4-NITRO-M-TOLYL)HYDANTOIN
Systematic Name English
2,4-IMIDAZOLIDINEDIONE, 5,5-DIMETHYL-3-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)-
Systematic Name English
NILUTAMIDE [EP MONOGRAPH]
Common Name English
NILUTAMIDE [USP MONOGRAPH]
Common Name English
NILUTAMIDE [MI]
Common Name English
RU 23908
Code English
NILUTAMIDE [MART.]
Common Name English
NSC-758683
Code English
NILUTAMIDE [VANDF]
Common Name English
RU-23908
Code English
NILUTAMIDE [USP-RS]
Common Name English
NILANDRON
Brand Name English
Nilutamide [WHO-DD]
Common Name English
NILUTAMIDE [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548158
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
NDF-RT N0000000243
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
NCI_THESAURUS C146993
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
WHO-VATC QL02BB02
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
WHO-ATC L02BB02
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
NDF-RT N0000175560
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID3034165
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
MESH
C021277
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
NCI_THESAURUS
C1173
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
WIKIPEDIA
NILUTAMIDE
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
RS_ITEM_NUM
1463472
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
PUBCHEM
4493
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
SMS_ID
100000083883
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
NSC
758683
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
MERCK INDEX
M7899
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1274
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
EVMPD
SUB09291MIG
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
FDA UNII
51G6I8B902
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
DRUG BANK
DB00665
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
DAILYMED
51G6I8B902
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
USAN
HH-48
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
DRUG CENTRAL
1933
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
CAS
63612-50-0
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
CHEBI
7573
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
INN
5755
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
IUPHAR
2864
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY
RXCUI
31805
Created by admin on Wed Jul 05 23:16:32 UTC 2023 , Edited by admin on Wed Jul 05 23:16:32 UTC 2023
PRIMARY RxNorm
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY